Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 442

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 2
Chunk 442
---
6 million of cibotercept-related expenses, primarily driven by a decrease of $6.1 million in clinical spend associated with our Phase 2 clinical trial and a net decrease of $3.5 million in manufacturing and preclinical activities; (iii) a decrease of $4.9 million in preclinical and development fees related to general pipeline development; (iv) a decrease of $1.0 million related to personnel expenses, which includes a decrease of $2.0 million of stock-based compensation costs, partially offset by increased severance costs. These decreases were partially offset by (a) an increase of $4.7 million in elritercept-related expenses, primarily driven by an increase of $5.3 million in manufacturing activities, partially offset by a decrease of $0.6 million in clinical spend associated with our ongoing Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, and the advancement of a Phase 3 clinical trial in patients with MDS, as clinical activities transition to Takeda; and (b) a net increase of $2.5 million in facilities, supplies, professional fees and other expenses. We expect research and development expenses to fluctuate from quarter to quarter depending on the timing of clinical trial activities, clinical manufacturing and other development activities. We expect that elritercept-related expenses will be eliminated once transitioned to Takeda.

General and Administrative Expenses 

General and administrative expenses were $35.1 million for the nine months ended September 30, 2025, compared to $30.1 million for the nine months ended September 30, 2024. The increase of approximately $5.0 million was primarily due to a net increase of $6.3 million in professional fees, insurance, facilities, supplies and other expenses partially offset by a decrease of $1.3 million in personnel expenses, which includes a decrease of $2.3 million stock-based compensation costs, partially offset by a net increase of $1.0 million in salaries and bonus, severance, benefits and other payroll costs.

Total Other Income, Net

Total other income, net was $20.0 million for the nine months ended September 30, 2025, compared to $16.3 million for the nine months ended September 30, 2024. The increase of approximately $3.8 million was driven by an increase of $3.9 million in dividend income, partially offset by an increase of $0.1 million